CLINICAL TRIAL: TREATMENT OF MELANOMA WITH WILD-TYPE P53 AND A 100B USING PENTA

临床试验：使用 PENTA 使用野生型 P53 和 A 100B 治疗黑色素瘤

• 批准号: 7951182
• 负责人: EDWARD A. SAUSVILLE
• 金额: $ 0.96万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951182
• 关键词: Clinical Research; Clinical Treatment; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Disease Progression; Funding; Grant; Institution; Mutation; Pentamidine; Pentas; Pharmaceutical Preparations; Protozoa; Refractory; Relapse; Research; Research Personnel; Resources; Source; TP53 gene; Time; Toxic effect; United States National Institutes of Health; melanoma; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Pentamidine is a clinically available anti-protozoal agent, which also inhibits the interaction of wild type p53 and S100B; these are frequently expressed in melanomas. The primary objective is to determine the response rate of relapsed and/or refractory melanoma that has previously been defined to express detectable S100B and to have a wild-type p53 mutation. Secondary objectives include assessment of toxicities, observation of time to disease progression, and observation of effect of drug treatment on expression of S100B and p53.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 五达二胺是一种临床上可用的抗多数剂，它也抑制了野生型p53和S100B的相互作用。这些经常在黑色素瘤中表达。主要目的是确定以前已定义为表达可检测到的S100B并具有野生型p53突变的复发和/或难治性黑色素瘤的反应率。次要目标包括评估毒性，观察疾病进展的时间以及观察药物治疗对S100B和p53表达的影响。